Manmade protein shows promise for cancer, macular degeneration

Potentially blinding blood vessel growth in the cornea resulting from eye injury or even surgery can be reduced by more than 50 percent with a new manmade protein, researchers say.

"We believe eventually we'll be able to use this protein to help patients in many situations where blood vessel formation is detrimental, including cancer, diabetic retinopathy and macular degeneration," says Dr. Balamurali K. Ambati, corneal specialist at the Medical College of Georgia and Augusta Veterans Affairs Medical Center. Dr. Ambati is corresponding author of the study published in the November issue of Investigative Ophthalmology & Visual Science.

The body can produce new blood vessels to promote healing after trauma, such as a corneal transplant, a significant corneal scratch from a contact lens or retinal oxygen deprivation caused by diabetes or aging. This natural response, called angiogenesis, becomes detrimental when new growth obstructs vision or when a tumor pirates the process to survive.

In an animal model, researchers used the protein they developed to reverse obstructive growth as long as one month after injury, says Dr. Ambati. That's a very long time after injury in a mouse's lifetime, indicating even well-established blood vessels are susceptible to intraceptor-mediated regression, he says.

This intraceptor traps vascular endothelial growth factor, or VEGF, inside the protein making machinery of a cell. It's made with a portion of a VEGF receptor called sflt-1, a free-floating receptor recently shown to help keep the cornea clear by taking up and effectively neutralizing VEGF. Although other molecules have an anti-angiogenic effect, sflt-1 was the only one they found that spurs corneal blood vessels when blocked. The work, published in October in Nature, was led by teams at MCG and the University of Kentucky.

"Now we have designed a novel recombinant molecule where we take a subunit of sflt-1 and couple it with a four-amino-acid peptide tail," he says. "The tail essentially handcuffs the manmade molecule within the protein-making machinery of the cell so that it stays there and anything that binds with it, namely VEGF, stays there too. So it's a very specific way of down-regulating a target protein."

In May 2005, Dr. Ambati and his colleagues published work in Investigative Ophthalmology & Visual Science showing the intraceptor helped reduce blood vessel development in the test tube and animal models for corneal injury and melanoma.

"Now we are talking about making them go away," says Dr. Ambati. While the work is still in the laboratory, it provides further evidence of the intraceptor's potential clinical application, he says.

The work shows the intraceptor prompts regression of blood vessels by inducing programmed cell death, or apoptosis, in the vascular endothelial cells that line the vessels.

"The biology of all this is showing this molecule interrupts the proper folding of proteins involved in existing blood vessels, which makes them die. It's a nice result," says Dr. Ambati.

Some existing anti-angiogenesis treatments target VEGF outside cells. "It is important to bind it within cells because certain cells, such as cancer and blood vessel cells, have the capability to produce their own VEGF and their own receptors," Dr. Ambati says. "Imagine trying to block from the outside a factory that has everything it needs inside. You have to throw a monkey wrench inside the factory and that is what we managed to do."

For the study, the manmade protein was injected directly into the cornea with a microneedle. "Ideally we would like to develop a topical eye drop with a long-term delivery system," says Dr. Ambati.

His research team is pursuing its work of the intraceptor's potential role in destroying blood vessels that help sustain cancers. They also are looking at a biodegradable polymer cage so they can encapsulate the intraceptor, tag it with a homing device for target cells and deliver it "like a missile carrying a payload" into the desired cells where it will slowly release the intraceptor, he says.

Source: Medical College of Georgia

Related stories:

Can stem cells heal damaged hearts? No easy answers, but some signs of hope
Recent studies indicate that infusing hearts with stem cells taken from bone marrow could improve cardiac function after myocardial infarction (tissue damage that results from a heart attack). But in a recent systematic review, Cochrane Researchers concluded that more clinical trials are needed to assess the effectiveness of stem cell therapies for heart patients, as well as studies to establish how these treatments work.
Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.
Medicine award kicks off Nobel Prize announcements
(AP) -- Two scientists who have won acclaim for research into the growth of cancer cells could be candidates for the Nobel Prize in medicine when the 2008 winners are presented on Monday, kicking off six days of Nobel announcements.
Discovery of natural compounds that could slow blood vessel growth
Using computer models and live cell experiments, biomedical engineers at the Johns Hopkins University School of Medicine have discovered more than 100 human protein fragments that can slow or stop the growth of cells that make up new blood vessels.
Breakthrough optical technology to assess colon cancer risk, accuracy
Researchers at NorthShore University HealthSystem (NorthShore) and Northwestern University have discovered that fiber optic technology can for the very first time effectively measure blood levels in the colonic lining (mucosa) in humans, thus having potential applications for analyzing risk of colon cancer.
Philips develops ultrasound-activated microbubbles for localized delivery of cancer drugs
(PhysOrg.com) -- Philips is developing an ultrasound-based drug delivery technology that is designed to increase the effectiveness and reduce the side effects of chemotherapy treatment for certain types of cancer.
Researchers create first model for retina receptors
A team of scientists at the University of Oklahoma Health Sciences Center has created the first genetic research model for a microscopic part of the eye that when missing causes blindness. The research appears in a recent issue of the Journal of Biological Chemistry.
Embryo implantation offers insight into infertility
(PhysOrg.com) -- A process that governs embryo implantation in the womb in humans has been identified for the first time. The Oxford University research, published in the journal PNAS, could shed light on what goes wrong when embryos fail to implant in the lining of the womb, a leading cause of infertility.

News discussion:

Manmade protein shows promise for cancer in Medicine & Health news